34 results about "Sub acute" patented technology

A method for determining respiration rate in a patient can include various parts. The respiration rate can be determined by measuring the heart's S2 split. The S2 split can be identified by observing the timing of the heart sounds. Other respiration related information, such as respiration phase and the occurrence of apnea, can be identified as well. A respiration monitor of this type may be useful for monitoring sub-acute patients, and outpatients. A sensor for the respiration monitor and an electrode for an ECG monitor may be combined into a single probe.

The present invention relates to the preparation and use of compositions for the treatment of skin disorders itchy and/or infected skin such as impetigo, acne (on face, forehead scalp and on the back of the body) and fungal infection of skin and nails. Whether the infection may be acute or chronic or sub-acute or acute on chronic.

As well as for the promotion of non carrier state of the human beings and animals from some pathogenic bacteria such as staphylococci. The compositions are based on extracts from the plants Cassia tora, Centratherum anthelminticum and/or Melia azadirachta. A variety of other herbal extracts may be included and the composition may take the form of a freeze dried or a spray dried powder or presence of this in a cream or ointment based on Ghee, or in a cream or ointment form developed with any other vehicle, or they may be in a powdered form without spray drying. That spray dried or freeze dried powder may be suspended in a suitable mouth wash or nasal drops. The herbs may be in a powdered form of suitable for preparing decoctions in hot water. Laboratory results are of Specimen Example 2. Specimen Example 1 I have found working on the patients clinically as broad spectrum covering pustules as well as fungal infections.

The invention provides a construction method for a clinic information quantification system. Clinic common parameters such as clinic essential characteristics of KD child patients, blood routine examination indexes and blood biochemical indexes as quantification indexes; a quantification method for assessing IVIG resistance, acute and sub-acute coronary artery lesions, coronary artery continuous lesions and recovery phase coronary artery aneurysms is established through the multi-factor logistic regression analysis method; the probability of occurrence of IVIG resistance and coronary artery lesions of the KD child patients and an assessment result (area under the curve, sensitivity and specificity) can be obtained, and then clinic treatment is directed, and follow-up visit is performed. The prediction efficiency for IVIGR of the quantification method is optimized obviously in comparison with the conventional methods; the quantification method predicts KD recovery phase coronary artery continuous lesions and recovery phase coronary artery aneurysms; the clinic parameters required by the quantification method come from the clinic essential characteristics, the blood routine examination indexes and the blood biochemical indexes, thereby facilitating application in primary hospital and exchange and promotion.

The invention discloses an application of saxifrage for preparing medicaments for treating hyperplasia of mammary glands, lipoma and thyroid gland carcinoid. The medicaments for the treating hyperplasia of mammary glands, the lipoma and the thyroid gland carcinoid have good effect. An acute and sub-acute toxicity experiment shows that the medicament has no toxic and side effect.

A method is disclosed of treating acute, sub-acute or chronic constipation in a patient having a condition requiring such treatment. The method includes administering a lipase inhibitor.

The invention relates to composition containing melatonin and catechin as well as an application of the composition, and in other words, composition used for foods, drugs or healthcare products contains melatonin and catechin. The combination use of melatonin and catechin in the composition can reduce toxic and side effects of catechin and greatly improve the safety of catechin, and the pharmacological action of catechin is not affected. The invention further relates to a novel application of melatonin, in particular to an application of melatonin to the preparation of the composition used for the healthcare products, the drugs or the foods; the composition is characterized by further containing catechin, wherein melatonin can reduce toxic and side effects of catechin, lethal toxicity of catechin and acute hepatotoxicity and sub-acute liver injury caused by catechin.

The invention relates to an establishing method for a rat central type superior mesenteric vein thrombosis model. The model is established by establishing an acute central type superior mesenteric vein thrombosis model, ligaturing the trunk root of a superior mesenteric vein at a time through a 7-0 no-damage nylon suture at the position 0.2 cm below the joint of the free superior mesenteric vein and a splenic vein, and conducting abdomen closing. A sub-acute central type superior mesenteric vein thrombosis model is established by placing a metal stick with the diameter of 1 mm and a superior mesenteric vein in parallel at the position 0.2 cm below the joint of the trunk of the free superior mesenteric vein and the splenic vein, ligaturing the superior mesenteric vein and the metal stick together through a 7-0 no-damage nylon suture, retreating the metal stick after ligation so that opened calibers of all rats can be kept basically consistent, and conducting abdomen closing. Food and water are freely fed in the next day. Abdomen opening is conducted again 48 hours later, the superior mesenteric vein is completely ligatured, and abdomen closing is conducted. Food and water are freely fed in the next day after the second operation. The rat central type superior mesenteric vein thrombosis model is suitable for superior mesenteric vein thrombosis intestinal pathology and pathophysiology research.

The invention discloses a preparation method for treating acute and subacute eczema, which comprises the following steps: 1) taking 20g of loratadine and 10g of neomycin sulfate and adding them to 250g of ethanol, stirring and dissolving to obtain a mixed solution for use ; 2) Sprinkle 4g ​​chitosan evenly to make it swell naturally; 3) Add 1.0g arbutin, keep stirring, and add ethanol to 1000mL; 4) Adjust the pH to 6.0~7.0, stir well, that is It can be used to treat acute and subacute eczema. In the present invention, loratadine and neomycin sulfate have obvious effects on inhibiting bacteria, and loratadine and neomycin sulfate are prepared into medicines. Due to the laurocapram transdermal technology, the penetration of the skin and limbs of the medicine is increased. , showing the superior curative effect of the coating agent on chronic eczema; the medicine for treating acute and subacute eczema made of chitosan has no greasy feeling, is easy to spread, has strong adhesion, and has a certain tear resistance. Convenient and non-irritating to the skin.